Company Description
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine.
The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets.
Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.
The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally.
It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories.
The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011.
HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 1997 |
| IPO Date | May 6, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 53 |
| CEO | John L. Lubniewski |
Contact Details
Address: 3430 E. Global Loop Tucson, Arizona 85706 United States | |
| Phone | 877-289-2615 |
| Website | htgmolecular.com |
Stock Details
| Ticker Symbol | HTGMQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001169987 |
| ISIN Number | US40434H3021 |
| Employer ID | 86-0912294 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| John L. Lubniewski | President, Chief Executive Officer and Director |
| Shaun D. McMeans | Senior Vice President, Chief Financial Officer, Secretary and Treasurer |
| Laura Lee Godlewski | Senior Vice President of Finance and Administration |
| Dr. Debra A. Gordon | Senior Vice President and Chief Legal Counsel |
| Dr. Patrick C. Roche | Senior Vice President of Research and Development |
| Dr. Stephen A. Barat Ph.D. | Senior Vice President of Therapeutics |
| Dr. Christina M. Carruthers Ph.D. | Vice President of Target Strategy and Early Development |
| Debrah Thompson | Vice President of Scientific Innovation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2023 | 25-NSE | Filing |
| Jun 8, 2023 | 8-K | Current Report |
| Jun 5, 2023 | 8-K | Current Report |
| May 24, 2023 | 8-K | Current Report |
| May 16, 2023 | 8-K | Current Report |
| May 11, 2023 | 10-Q | Quarterly Report |
| May 10, 2023 | 8-K | Current Report |
| Apr 25, 2023 | 8-K | Current Report |
| Mar 30, 2023 | 10-K | Annual Report |
| Feb 13, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |